BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31676945)

  • 21. Oncogenomic analysis identifies novel biomarkers for tumor stage mycosis fungoides.
    Dong Z; Zhu X; Li Y; Gan L; Chen H; Zhang W; Sun J
    Medicine (Baltimore); 2018 May; 97(21):e10871. PubMed ID: 29794791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCR10 is expressed in cutaneous T-cell lymphoma.
    Notohamiprodjo M; Segerer S; Huss R; Hildebrandt B; Soler D; Djafarzadeh R; Buck W; Nelson PJ; von Luettichau I
    Int J Cancer; 2005 Jul; 115(4):641-7. PubMed ID: 15700309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular advances in cutaneous T-cell lymphoma.
    Bastidas Torres AN; Najidh S; Tensen CP; Vermeer MH
    Semin Cutan Med Surg; 2018 Mar; 37(1):81-86. PubMed ID: 29719024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NLRP3 Regulates IL-4 Expression in TOX
    Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
    Front Immunol; 2021; 12():668369. PubMed ID: 34220814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
    Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
    Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
    Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma.
    Chevret E; Andrique L; Prochazkova-Carlotti M; Ferrer J; Cappellen D; Laharanne E; Idrissi Y; Boettiger A; Sahraoui W; Ruiz F; Pham-Ledard A; Vergier B; Belloc F; Dubus P; Beylot-Barry M; Merlio JP
    Blood; 2014 Mar; 123(12):1850-9. PubMed ID: 24470590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
    Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
    Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
    Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
    J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
    van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
    J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).
    Litvinov IV; Netchiporouk E; Cordeiro B; Doré MA; Moreau L; Pehr K; Gilbert M; Zhou Y; Sasseville D; Kupper TS
    Clin Cancer Res; 2015 Jun; 21(12):2820-9. PubMed ID: 25779945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
    Yumeen S; Girardi M
    Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
    García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.
    Herrera A; Cheng A; Mimitou EP; Seffens A; George D; Bar-Natan M; Heguy A; Ruggles KV; Scher JU; Hymes K; Latkowski JA; Ødum N; Kadin ME; Ouyang Z; Geskin LJ; Smibert P; Buus TB; Koralov SB
    Blood; 2021 Oct; 138(16):1456-1464. PubMed ID: 34232982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.
    Mao X; Orchard G; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
    J Invest Dermatol; 2006 Jun; 126(6):1388-95. PubMed ID: 16614728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.
    Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.